Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes
Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.
You may also be interested in...
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.